Search

Search Constraints

You searched for: Author/Creator Alonzo, Todd

Search Results

2. Early discharge as a mediator of greater ICU‐level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. (29th July 2016)

3. Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Issue 1 (December 2016)

5. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Issue 1 (December 2015)

6. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Issue 1 (December 2015)

8. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. Issue 1 (December 2016)